HPLC法测定八维钙锌片中烟酰胺、维生素B_1、B_2、B_6的含量

目的:建立RP-HPLC法测定八维钙锌片中烟酰胺、维生素B1、B2、B6的含量。方法:采用Phenom enex C18柱(150 mm×4.6 mm,5μm);流动相为庚烷磺酸钠溶液(取庚烷磺酸钠0.6 g,加冰醋酸6 mL与三乙胺1 mL,加水至1000 mL,用2 mol.L-1氢氧化钠溶液调节pH至3.80)-甲醇(80∶20);紫外检测波长为280 nm;流速为1 mL.m in-1。结果:烟酰胺的线性范围为26.463~423.40μg.mL-1(r=0.9999),平均回收率为100.8%,RSD为1.4%(n=9);维生素B1的线性范围为3.90~62.4μg.mL-1(r=0.9999),平均回收率为100.9%,RSD为1.3%(n=9);维生素B2的线性范围为4.64~74.24μg.mL-1(r=0.9999),平均回收率为99.7%,RSD为1.8%(n=9);维生素B6的线性范围为4.95~79.28μg.mL-1(r=0.9999),平均回收率为100.3%,RSD为2.8%(n=9)。结论:本方法操作简便,结果准确、可靠,可同时测定八维钙锌片中烟酰胺、维生素B1、B2、B6的含...     

HPLC法测定多维生素糖浆中D-泛醇含量

目的建立HPLC-UV法测定多维生素糖浆中D-泛醇的含量。方法采用Agela AQ-C18柱;流动相A为0.05mol.L-1磷酸二氢钾-乙腈(99∶1);流动相B为0.05mol.L-1磷酸二氢钾-乙腈(80∶20);梯度洗脱;流速为1.0mL.min-1;检测波长为214nm。结果 D-泛醇的浓度在0.02~0.4mg.mL-1范围内线性关系良好(r=1.0000,n=5);平均回收率为99.8%(RSD=0.4%,n=9)。结论本分析方法快速、灵敏,分离度良好,结果准确可靠,可作为多维生素糖浆的质量控制项目之一。     

HPLC法测定复合维生素B片中维生素B1、B2、B6的含量

目的 建立高效液相色谱法测定复合维生素B片中维生素B1、维生素B2、维生素B6的含量.方法 色谱柱:Wondasil C18色谱柱,流动相为醋酸-醋酸钠缓冲液(pH 4.5)-甲醇(65∶35),流速为1.0 mL·min-1,检测波长为270 nm.结果 维生素B1、维生素B2、维生素B6浓度分别在0.6 μg·mL-1～0.75 mg·mL-1、0.3 μg·mL-1～0.62 mg·mL-1、80～415 μg·mL1范围内与峰面积线性关系良好.结论 该方法简便、快速、准确可靠,可用于复合维生素B片中维生素B1、维生素B2、维生素B6的含量测定.     

HPLC法测定五维赖氨酸口服溶液中维生素C、维生素B6、烟酰胺的含量

目的建立HPLC法测定五维赖氨酸口服溶液中维生素C、维生素B6、烟酰胺的含量方法。方法采用AlltimaTMC18色谱柱,流动相:0.03mol·L-1磷酸氢二铵溶液(加入0.05%庚烷磺酸钠和0.2%三乙胺,用磷酸调节pH至3.0)-甲醇,梯度洗脱,检测波长:277nm,流速:1.0 mL·min-1,柱温:30℃。结果维生素C、维生素B6、烟酰胺分别在2.587~20.670μg(r=0.9999)、0.123~0.980μg(r=1.0000)、1.126~9.007μg(r=1.0000)范围内线性关系良好,平均回收率分别为100.00%(RSD=0.10%)、99.06%(RSD=0.28%)、99.67(RSD=0.31%)(n=9)。结论本法简便、准确、可靠,可用于五维赖氨酸口服溶液中维生素C、维生素B6、烟酰胺的质量控制。     

HPLC 法测定多维元素胶囊（15）中烟酰胺、维生素B1、维生素B2、维生素B6的含量

目的:建立高效液相色谱法测定多维元素胶囊(15)中的烟酰胺、维生素B1、维生素B2、维生素B6的含量.方法:采用Boston Green ODS C18柱(250 mm×4.6 mm,5 μm);流动相:庚烷磺酸钠溶液(取庚烷磺酸钠0.941 g,加冰乙酸10 ml,加水1 000 ml溶解,用NaOH试液调节pH至3.8)-甲醇(70:30);进样量:20 μl;检测波长为280 nm;柱温:30℃;流速1.0 ml·min-1.结果:烟酰胺、维生素B1、维生素B2、维生素B6分别在38.83～349.44,9.88～88.94,4.03～36.25,3.97～35.77 μg·ml-1范围内线性关系良好(r≥0.999 6);平均回收率分别为98.7%(RSD=0.89%),98.7%(RSD=1.03%),99.0%(RSD=1.03%),99.8%(RSD=1.49%).结论:该方法准确,灵敏度高,重复性好,可作为多维元素胶囊(15)的质量控制方法之一.     

超高效液相色谱法测定复合维生素B片中4种成分的含量

目的 建立复合维生素B片中维生素B1、维生素B2、烟酰胺及维生素B6的超高效液相色谱含量测定方法.方法 采用Waters Acquity UPLC BEH C18色谱柱(2.1 mm×100 mm,1.7 μm),以0.005 mol·L-1 庚烷磺酸钠溶液(含0.15%的三乙胺,用冰醋酸调节pH值至4.3)-甲醇(80∶20)为流动相,流速为0.2 mL·min-1,柱温为30 ℃,检测波长280 nm.结果 维生素B1、维生素B2、烟酰胺及维生素B6分别在0.006~0.24、0.003~0.12、0.02~0.8、0.003~0.12 μg范围内呈现良好的线性关系,检出限(S/N=3)分别为0.32、0.14、1.25和0.18 ng,平均回收率分别为97.9%、100.1%、98.7%、98.1%,RSD均小于2.0%.结论 该方法简便快速,准确,重复性好,可用于复合维生素B 片4 种成分的含量测定.     

复合维生素注射液中6种维生素的含量测定

目的:建立高效液相色谱同时测定复合维生素注射液中6种维生素的方法。方法:采用离子对高效液相色谱法,以0.005 mol.L-1戊烷磺酸钠的0.1%磷酸溶液为流动相A,0.005 mol.L-1戊烷磺酸钠的0.1%磷酸溶液-乙腈(20∶80)为流动相B,进行梯度洗脱;Inertsil(ODS-2)色谱柱,流速为1 mL.min-1,检测波长为210 nm,柱温为30℃。结果:维生素C、烟酰胺、维生素B1、维生素B2、维生素B6,泛醇之间能够达到很好的分离,精密度、回收率、稳定性均符合要求。结论:该方法能同时测定6种维生素的含量,且简单、快速、灵敏度高、重复性好,可用于批次样品的含量测定及质量控制。     

反相离子对色谱法测定复方维生素片中3种水溶性维生素的含量

目的:建立反相离子对色谱法测定复方维生素片中维生素B1、维生素B2、维生素B6含量的方法。方法:以己烷磺酸钠作为离子对试剂,采用Diamonsil C18(250 mm×4.6 mm,5μm)柱,同时测定复方维生素片中维生素B1、B2和B6的含量。结果:维生素B1、B2和B6分别在6.3～14.7μg.mL-1(r=0.999 8),7.2～16.8μg.mL-1(r=0.999 5),6.3～14.7μg.mL-1(r=0.999 6)范围内线性关系良好,平均回收率分别为100.08%(RSD=0.84%,n=9),100.35%(RSD=1.26%,n=9),99.41%(RSD=1.10%,n=9)。结论:本方法快速、简便、准确,分离效果好,辅料无干扰,可用于该类制剂中维生素B1,B2和B6的含量测定及质量控制研究。     

小儿康糖浆中的4种维生素的含量测定

目的:用HPLC法测定小儿康糖浆中烟酰胺、维生素B1、维生素B2和维生素B6的含量.方法:采用十八烷基硅烷键合硅胶为填料(purtir C18 200mm×4.6mm,5μm,Zichrom),以三乙胺-冰醋酸-甲醇-0.008mol/L己烷磺酸钠溶液(0.2:7.5:175:820)为流动相,流速为1.0ml·min-1,检测波长为270nm.结果:烟酰胺、维生素B1、维生素B2和维生素B6分别在0.152～0.610mg·ml-1、0.052～0.313mg·ml-1、0.010～0.065mg·ml-1和0.043～0.257mg·ml-1范围内呈良好线性关系,平均回收率分别为100.7%(RSD=1.14%,n=9)、99.4%(RSD=0.52%,n=9)、100.4%(RSD=0.82%,n=9)和100.3%(RSD=0.92%,n=9).结论:本法结果准确可靠,专属,能有效控制产品质量.     

HPLC法测定维生素B族片中3种组分的含量

目的 采用高效液相色谱法同时测定维生素B族片中三种维生素B(维生素B1,维生素B2,维生素B6)的含量.方法 采用C18柱,以0.005mol·L-1的庚烷磺酸钠溶液(含0.5%冰醋酸和0.05%三乙胺)-甲醇(65:35,v:v)为流动相,流速为1.0mL·min-1.紫外检测波长为280nm.结果 本实验中维生素B1,B2,B6线性范围分别为2.964~74.1mg·mL-1,2.934~73.35mg·mL-1,2.996~74.9mg·mL-1,回收率分别为97.5%,99.7%,100.5%,RSD分别为1.21%,1.5%,0.9%.结论 本法快速、简便、分离效果好,适用于多维片中维生素B1,维生素B2,维生素B6的质量控制.     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.